Using Acetazolamide to Prevent Kidney Injury in Cancer Patients on High-Dose Methotrexate
Author Information
Author(s): Lin Lindon, Batt Tracey, Gregory M. Peterson, Cheungpasitporn Wisit
Primary Institution: University of Tasmania
Hypothesis
Does acetazolamide reduce the risk of acute kidney injury in patients receiving high-dose methotrexate?
Conclusion
Acetazolamide did not appear to reduce the risk of acute kidney injury in this pilot study.
Supporting Evidence
- AKI occurred in 0/7 cycles with acetazolamide versus 14/59 cycles without.
- Age was identified as the strongest independent risk factor for AKI.
- Patients receiving beta-lactam antibiotics had a higher incidence of AKI.
Takeaway
This study looked at whether a medicine called acetazolamide could help protect cancer patients' kidneys when they take a strong chemotherapy drug. It found that acetazolamide didn't really help.
Methodology
This was a retrospective cohort pilot study analyzing data from patients who received high-dose methotrexate.
Potential Biases
There could have been selection bias regarding the decision to administer acetazolamide.
Limitations
The study was limited by a small sample size.
Participant Demographics
The study included 31 patients, with a median age of 64 years, comprising 71% males and 29% females.
Statistical Information
P-Value
0.33
Confidence Interval
1.009–1.2358
Statistical Significance
p = 0.33
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website